COMMUNIQUÉS West-GlobeNewswire

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
30/04/2026
Grants OPKO a 15% equity interest in Nicoya MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an [...]
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
30/04/2026
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
AVITA Medical Names Cary Vance as Chief Executive Officer
30/04/2026
Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., [...]
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
30/04/2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical [...]
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
30/04/2026
Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician interest at recent [...]
Kriya Announces Presentations at ASGCT 2026 Highlighting Advances Across Gene Therapy Platform
30/04/2026
Kriya’s integrated R&D and manufacturing platform is designed to make gene therapies accessible for more common chronic diseases ASGCT presentations reflect Kriya’s commitment to continuously optimize its platform [...]
Vicarious Surgical Reports First Quarter 2026 Financial Results
30/04/2026
WALTHAM, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCQB: RBOT), a next-generation robotics technology company seeking to improve lives by transforming [...]
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
30/04/2026
The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
30/04/2026
ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
TOMI Environmental Solutions Signs Letter of Intent for a Merger with Carbonium Core, Inc., a U.S.-Based Producer of Nuclear-Grade Graphite for Advanced Reactors and Infrastructure Demands of AI Data Centers
30/04/2026
Establishes domestic platform in advanced graphite, addressing a multi-billion-dollar end market underpinned by U.S. supply-chain reshoring and next-generation nuclear and AI data center demands FREDERICK, Md., April 30 [...]
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
30/04/2026
WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]
Vireo Growth to Acquire FLUENT in All-Stock Transaction
30/04/2026
MINNEAPOLIS and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo”), a multi-state cannabis operator, and FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “ [...]
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
30/04/2026
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori [...]
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
30/04/2026
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSA Advancing ATH434 toward pivotal Phase 3 program; on track for End-of-Phase 2 FDA [...]
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2026
30/04/2026
BANNOCKBURN, Ill., April 30, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
30/04/2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a company developing advanced artificial intelligence solutions for [...]
AC Immune First Quarter 2026 Financial and Corporate Updates
30/04/2026
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 [...]
Aurora Spine Corporation Announces Record Fourth Quarter and FY25 Financial Results
30/04/2026
– Q4 revenue surpasses $5 million threshold – –Company to host conference call today, April 30 th at 11am ET/8am PT – NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April [...]
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
30/04/2026
~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~ ~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential Phase III design and [...]

Pages